Comparative Pharmacology
Head-to-head clinical analysis: FAMVIR versus HERPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMVIR versus HERPLEX.
FAMVIR vs HERPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famciclovir is a prodrug that is rapidly converted to penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thereby inhibiting viral DNA synthesis and replication.
Inhibits viral DNA polymerase after phosphorylation to acyclovir triphosphate, leading to chain termination and inhibition of herpes simplex virus replication.
250 mg orally three times daily for 7 days for herpes zoster; 125 mg orally twice daily for 5 days for recurrent genital herpes; 250 mg orally twice daily for 7 days for first-episode genital herpes; 500 mg orally twice daily for 7 days for herpes zoster in immunocompromised patients; 500 mg orally twice daily for 7 days for recurrent mucocutaneous herpes in HIV patients.
Acyclovir 200 mg orally 5 times daily for 10 days for initial genital herpes; 400 mg orally twice daily for suppressive therapy; 5-10 mg/kg IV every 8 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life of penciclovir is approximately 2–3 hours in patients with normal renal function; extends to 9–18 hours in severe renal impairment (CrCl <30 mL/min).
2.5–3.3 hours in adults with normal renal function; prolonged to 10–20 hours in anuria (CrCl <10 mL/min); requires dose adjustment in renal impairment
Renal: 60–70% as penciclovir via tubular secretion and glomerular filtration; fecal: <10%; biliary: <1%.
Renal: ~90% as unchanged drug via glomerular filtration and tubular secretion; minor biliary/fecal elimination (<2%)
Category C
Category C
Antiviral
Antiviral